News
AMPH
41.24
+1.00%
0.41
New Strong Sell Stocks for April 26th
NASDAQ · 8h ago
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Amphastar Pharmaceuticals's (NASDAQ:AMPH) returns 22% of its earnings to shareholders. The company has a net income growth of 42% over the last five years. Its ROE of 22% is better than the industry average of 18%. The company's earnings growth is expected to slow down over the next few years. Amphastar pharmaceuticals has a good return on equity of 22%. It is worth looking at the company's ROE in conjunction with its earnings growth.
Simply Wall St · 8h ago
Weekly Report: what happened at AMPH last week (0415-0419)?
Weekly Report · 4d ago
Oversold Conditions For Amphastar Pharmaceuticals (AMPH)
NASDAQ · 04/18 15:58
Amphastar Pharmaceuticals Poised for Growth: Strong Generic Pipeline and Strategic Marketing Drive Buy Rating
TipRanks · 04/17 15:35
Weekly Report: what happened at AMPH last week (0408-0412)?
Weekly Report · 04/15 09:09
Commit To Buy Amphastar Pharmaceuticals At $22.50, Earn 18.5% Annualized Using Options
NASDAQ · 04/12 15:35
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amphastar Pharmaceuticals (AMPH), Ascendis Pharma (ASND) and AMN Healthcare Services (AMN)
TipRanks · 04/12 13:41
Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) is the inhaled glucagon product for severe hypoglycemia. Baqsimi is projected to reach peak sales of $250-270 million in 2023. Needham keeps the Hold rating for Amphastar.
Benzinga · 04/10 19:23
Needham Reiterates Hold on Amphastar Pharma
Benzinga · 04/10 11:24
Needham Sticks to Its Hold Rating for Amphastar Pharmaceuticals (AMPH)
TipRanks · 04/10 10:56
Amphastar Pharmaceuticals (NASDAQ:AMPH) Offers Savvy Value Investors a Window of Opportunity
TipRanks · 04/09 12:08
Weekly Report: what happened at AMPH last week (0401-0405)?
Weekly Report · 04/08 09:09
Weekly Report: what happened at AMPH last week (0325-0329)?
Weekly Report · 04/01 09:09
Is Amphastar (AMPH) a Buy as Wall Street Analysts Look Optimistic?
NASDAQ · 03/27 13:30
Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has US$589.4m of debt on its balance sheet. The company uses debt to fund growth, but is this a concern for shareholders? Amphastar pharmaceuticals has a strong balance sheet and is in a good position to pay off its debt. The firm grew its EBIT by 86% over the last year and has a healthy free cash flow. Amphastr Pharmaceuticals's debt is less than 1.4 times its earnings, which is considered to be conservative.
Simply Wall St · 03/27 10:59
Amphastar Pharmaceuticals (AMPH) Registers a Bigger Fall Than the Market: Important Facts to Note
NASDAQ · 03/26 21:50
Weekly Report: what happened at AMPH last week (0318-0322)?
Weekly Report · 03/25 09:09
New Strong Sell Stocks for March 18th
NASDAQ · 03/18 13:15
Weekly Report: what happened at AMPH last week (0311-0315)?
Weekly Report · 03/18 09:09
More
Webull provides a variety of real-time AMPH stock news. You can receive the latest news about Amphastar Pharma through multiple platforms. This information may help you make smarter investment decisions.
About AMPH
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.